TRN-110 is under clinical development by Tris Pharma and currently in Pre-Registration for Attention Deficit Hyperactivity Disorder (ADHD). According to GlobalData, Pre-Registration drugs for Attention Deficit Hyperactivity Disorder (ADHD) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how TRN-110’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TRN-110 is under development for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatrics and adults. The therapeutic candidate is administered through oral route. It is developed based on liquiXR technology.
Tris Pharma overview
Tris Pharma discovers, develops and commercializes over-the-counter and generic products. The company’s pipeline product candidates include TRN-110, TRN-124, TRN-125, TRN-167, TRN-123, TRN-152, TRN-148, TRN-219, TRN-213 and TRN-226. Its generic products include colesevelam, dexmethylphenidate, dextroamphetamine, doxycycline Hyclate, doxycycline hyclate, droxidopa, febuxostat, hydrocodone, hydrocodone polistirex, lacosamide, methylphenidate, morphine sulfate and paliperidone ER. Tris Pharma is headquartered in South Brunswick, New Jersey, the US.
For a complete picture of TRN-110’s drug-specific PTSR and LoA scores, buy the report here.